PMID- 23317197
OWN - NLM
STAT- MEDLINE
DCOM- 20130702
LR  - 20220321
IS  - 2476-762X (Electronic)
IS  - 1513-7368 (Linking)
VI  - 13
IP  - 11
DP  - 2012
TI  - P53 and PCNA is positively correlated with HPV infection in laryngeal 
      epitheliopapillomatous lesions in patiets with different ethnic backgrounds in 
      Xinjiang.
PG  - 5439-44
AB  - OBJECTIVE: To explore the correlation of human papillomavious (HPV) infection 
      with expression of p53 and proliferating cell nuclear antigen (PCNA) in patients 
      with different ethnicity in Xinjiang, China. METHODS: 166 biopsy specimens from 
      83 laryngeal squamous cell carcinomas (LSCC), 63 laryngeal papillomas (LP), and 
      20 laryngeal inflammatory polyps (LIP) were included in this study. HPV infection 
      was determined by polymerase chain reaction (PCR) using specific types of HPV 
      primers. Expression of p53 and PCNA was assessed using immunohistostaining. 
      RESULTS: The frequency of HPV 6/11 was higher in LP (33.3%) than in LSCC (9.6%) 
      (P<0.0005), whereas the frequency of HPV 16/18 was higher in LSCC (37.3%) than in 
      LP (6.3%) (P<0.0005). Patients of the Han ethnic group with LSCC had a higher 
      infection rate with HPV 6/11 or HPV 6/11 and HPV 16/18 coinfection than those of 
      Uygur and Kazak ethnicity (P<0.05). Overexpression of p53 and PCNA were higher in 
      LSCC (62.7%, 57.8%) than in LP (38%, 33.3%) (P<0.005, and P<0.005, respectively). 
      That of p53 was not associated with lymph-node metastases and clinical stages, 
      but overexpression of PCNA closely correlated with clinical stage. CONCLUSIONS: 
      These results strongly implicate HPV6/11 infection in the carcinogenesis of LSCC 
      and LP, respectively. There was a higher coincidence of increased malignancy of 
      laryngeal tumors with overexpression of p53 and PCNA. Overexpression of p53 may 
      serve as an early risk marker for malignant transformation in HPV infected cells 
      while the overexpression of PCNA may serve as a late marker for progression of 
      LSCC.
FAU - Sun, Jie
AU  - Sun J
AD  - Department of ENT, the First Affiliated Hospital of Xinjiang Medical University, 
      China.
FAU - Xiong, Ju
AU  - Xiong J
FAU - Zhen, Yan
AU  - Zhen Y
FAU - Chen, Zhao-Lun
AU  - Chen ZL
FAU - Zhang, Hua
AU  - Zhang H
LA  - eng
PT  - Journal Article
PL  - Thailand
TA  - Asian Pac J Cancer Prev
JT  - Asian Pacific journal of cancer prevention : APJCP
JID - 101130625
RN  - 0 (DNA, Viral)
RN  - 0 (Proliferating Cell Nuclear Antigen)
RN  - 0 (TP53 protein, human)
RN  - 0 (Tumor Suppressor Protein p53)
SB  - IM
MH  - Adult
MH  - Carcinoma, Squamous Cell/ethnology/*metabolism/virology
MH  - China
MH  - DNA, Viral/genetics
MH  - Female
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - Laryngeal Neoplasms/ethnology/*metabolism/virology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Papilloma/ethnology/*metabolism/virology
MH  - Papillomaviridae/genetics
MH  - Papillomavirus Infections/ethnology/*metabolism/virology
MH  - Polymerase Chain Reaction
MH  - Prognosis
MH  - Proliferating Cell Nuclear Antigen/*metabolism
MH  - Tumor Suppressor Protein p53/*metabolism
MH  - Tumor Virus Infections/ethnology/*metabolism/virology
EDAT- 2013/01/16 06:00
MHDA- 2013/07/03 06:00
CRDT- 2013/01/16 06:00
PHST- 2013/01/16 06:00 [entrez]
PHST- 2013/01/16 06:00 [pubmed]
PHST- 2013/07/03 06:00 [medline]
AID - 10.7314/apjcp.2012.13.11.5439 [doi]
PST - ppublish
SO  - Asian Pac J Cancer Prev. 2012;13(11):5439-44. doi: 10.7314/apjcp.2012.13.11.5439.